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Abstract
Objective—To estimate the probability of complete clinical response and toxicity of paclitaxel as 
second-line chemotherapy in measurable disease patients with malignant tumors of the ovarian 
stroma, and to evaluate the value of inhibin for predicting response.
Methods—Thirty-one patients with histologically confirmed ovarian stromal tumor were 
enrolled from 2000 to 2013. Patients were required to have measurable recurrent disease, and to 
have received only one prior chemotherapy regimen. Paclitaxel 175 mg/m2 was administered over 
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a 3 hour infusion, cycling every 21 days. Inhibin levels were drawn within two weeks of initiation 
of treatment.
Results—Of 31 women enrolled, there was only one complete response (3.2%), and partial 
response in eight of 31 cases (25.8%). The pretreatment inhibin level for the single patient who 
had complete response was 88 pg/mL. Median progression-free survival was 10.0 months and 
overall survival was 73.6 months. Myelosuppression was common with 12 of 31 patients (38.7%) 
suffering grade 3 or 4 neutropenia, leukopenia, or anemia.
Conclusion—There were too few complete responses to warrant continued evaluation of 
paclitaxel as a single agent treatment for women with recurrent malignant ovarian stromal tumors 
with measurable disease according to the primary objective of the study. Toxicity of the regimen 
was acceptable. Pretreatment inhibin is not a reliable tumor marker as it was not elevated in the 
majority of patients.
Keywords
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1. Introduction
Malignant sex cord stromal cell tumors comprise 2–8% of all ovarian cancers [1]. Stromal 
tumors can be benign or malignant and express a variety of markers and hormones. 
Granulosa cell tumors are the most common malignant stromal tumor. The less common 
ovarian sex cord stromal tumors include Sertoli–Leydig types which may produce 
androgenic hormones and span benign to malignant phenotypes. Rare stromal tumors 
include granulosa cell–theca cell tumor, steroid cell tumor, gynandroblastoma, unclassified 
sex cord stromal tumors, and sex cord tumor with annular tubules.
Patients with stage I malignant stromal tumors have a favorable prognosis with surgical 
treatment alone, however, women with advanced and recurrent disease have a poor 
prognosis and are commonly treated with chemotherapy. Most studies have focused on the 
behavior of these tumors which present in early stage when adjuvant therapy is not needed. 
However, these tumors are on occasion indolent and late recurrences can occur.
Due to the rarity of these tumors, defining adjuvant and therapeutic regimens has been 
difficult. Studies have evaluated agents such as 5-fluorouracil, vincristine, dactinomycin, and 
cyclophosphamide. None of these agents attained significant clinical response [2, 3]. Case 
reports and series have described varying degrees of success with combinations of cisplatin, 
doxorubicin, cyclophosphamide, and altretamide [4–7]. In 1996, Gershenson et al. proposed 
treatment with a combination of bleomycin, cisplatin, and etoposide (BEP) [8]. In that study 
of nine patients, of the six with measurable disease there was a 33% complete response and 
50% partial response observed. In 1999, a Gynecologic Oncology Group (GOG) study by 
Homesley et al. evaluated this similar regimen with 16 women with primary disease and 41 
with recurrent disease, and confirmed activity of this combination. The end point used for 
response was second-look laparotomy. Of patients undergoing second-look laparotomy, 37% 
(14/38) had negative findings [9]. As a result of this study, BEP became the standard of care 
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for treatment of stromal cell tumors. A few clinical trials have studied the more rare 
androgen-based sex cord stromal tumors and none resulted in clear clinical recommendation 
for treatment. Consequently, androgenbased sex cord stromal tumors have been combined 
with granulosa cell tumors for the purpose of study and treatment.
Paclitaxel, originally derived from the Pacific Yew tree, belongs to a class of drugs whose 
prime mechanism of action is the disruption of microtubule activity and thus is considered a 
mitotic inhibitor. In the pivotal study by McGuire et al., a taxane/platin regimen emerged as 
the standard of care for treatment of epithelial ovarian cancer [10]. GOG-187 was designed 
to evaluate the clinical response and toxicity of single agent paclitaxel as second-line therapy 
in patients with measurable recurrent malignant stromal tumor and to evaluate the value of 
inhibin A and inhibin B as predictors of tumor response.
2. Materials and methods
Women diagnosed with histologically confirmed ovarian stromal tumor were eligible for 
enrollment. Initially, patients with any measurable disease were enrolled including those 
receiving first-line therapy. The protocol was later amended, requiring patients to have 
recurrent disease and to have received only one previous chemotherapy regimen. Measurable 
disease was required as defined by GOG Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria [11]. Stromal histology included: granulosa cell tumor, granulosa cell-
theca cell tumor, Sertoli–Leydig cell tumor, steroid cell tumor, gynandroblastoma, 
unclassified sex cord stromal tumors, and sex cord tumor with annular tubules. Patients were 
required to have GOG performance status of 0, 1, or 2. Histologic confirmation was 
performed by central review by the GOG Pathology Committee. Adequate bone marrow 
function was required as defined by: absolute neutrophil counts (ANC) greater than or equal 
to 1500/l, platelet count greater than 100,000/l, hepatic function (bilirubin ≤ 1.5 times 
institutional upper limit of normal), and SGOT and alkaline phosphatase ≤ 2.5 times 
institutional upper limit of normal.
The GOG protocol and consent were approved by each participating institution. The 
protocol was reviewed annually by the Institutional Review Board. Patients were enrolled 
after obtaining informed consent. Each patient had been treated with first-line therapy as 
chosen by her physician. Patients with persistent/stable disease or progression were eligible 
for trial entry. Serum inhibin A and inhibin B were drawn to monitor response to therapy. 
Paclitaxel at 175 mg/m2 was administered over a 3 hour infusion, cycling every 21 days until 
progression or adverse events prohibited additional treatment. When a patient had a 
complete response, two additional courses of paclitaxel were administered. Maximum body 
surface area calculated for dosing was 2.0 m2 as per GOG Chemotherapy procedures 
manual. CT of the chest, abdomen and pelvis was performed within 28 days of initiation of 
treatment and repeated every other cycle. If disease was followed by physical exam, 
measurements were repeated every cycle while on therapy. Inhibin levels were drawn within 
two weeks of initiation of treatment.
Patients received paclitaxel administered at 175 mg/m2 IV over 3 h on day one of a 21-day 
cycle. Pre-medication for paclitaxel infusion was at the discretion of the investigator, 
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however, oral/IV dexamethasone, IV diphenhydramine, and IV H2 blockers were 
recommended.
Patients continued receiving treatment if white blood cell count was N 3000/mcl and platelet 
counts were ≥ 100,000/mcl. Modification was made for patients with febrile neutropenia or 
sepsis. For these patients, a dose reduction of one level, to a dose of 135 mg/m2, was 
initiated. Use of G-CSF was allowed at the discretion of the investigator. A delay of greater 
than two weeks resulted in a dose reduction to 135 mg/m2. Patients who were delayed more 
than three weeks were removed from study. Re-escalation was allowed if a dose reduction 
was initiated due to low white count or platelet count in a previous cycle or for patients who 
experienced Grade 0/1 hematologic toxicity without other organ toxicity. In these cases, 
dosing was escalated by one level for each subsequent course until maximum dosing was 
reached. Grade 3 or grade 4 GI toxicity required a two dose level reduction, to a dose of 110 
mg/m2, if the toxicities were due to mucositis or diarrhea. Any other grade 4 GI toxicity was 
accompanied by a dose reduction to 135 mg/m2. In regard to hepatic toxicity, grade 3 or 
grade 4 hepatic toxicity required one dose level reduction in subsequent courses. For renal 
toxicity of grade 2 or greater, not clearly due to obstructive uropathy, a dose reduction to 135 
mg/m2 was performed.
The primary measure of treatment efficacy in this study is complete clinical response. This 
study implemented an optimal and flexible two-stage accrual design [12]. The number of 
individuals enrolled during each stage of the study was allowed to vary in order to account 
for the complexities of managing a multi-institutional study or the potential for enrolling 
patients who could eventually be deemed ineligible following centralized review. During the 
first stage of accrual between 15 and 22 patients were to be enrolled, and at least one 
complete response out of the 15–16 enrolled or two complete responses out of the 17–22 
enrolled was required in order to advance to the second stage of accrual. If the second stage 
of accrual was warranted, then enrollment would continue until a total of 30–37 eligible 
patients were enrolled onto the study. If there were more than two complete responses out of 
30–31 enrolled or three complete responses out of 32–37, then the regimen would be 
deemed sufficiently active to warrant further investigation. This design provides an average 
of 90% power for detecting a treatment that has a true 20% complete response probability, 
when the type I error is set to 10% for a one-sided test of the null hypothesis that the true 
complete response rate is no more than 5%. These type I and II errors are averaged over all 
allowable enrollment configurations [12].
3. Results
3.1. Patient characteristics
During the first stage of accrual 15 patients were enrolled from 2000 to 2004 and one 
complete responder was reported in this cohort. Therefore, a second stage of accrual was 
initiated during which 16 additional patients were enrolled from 2005 to 2012. In total, 31 
patients, all with recurrent disease, were enrolled in this study. Patient characteristics are 
summarized in Table 1. The majority of patients were non-Hispanic white (18/31). The 
majority had a performance status of 0 (25/31). Three patients had been treated with prior 
radiation, and one patient had had prior immunotherapy. Twenty-four patients had received 
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prior chemotherapy, and three patients had had previous hormone therapy. Pretreatment 
inhibin levels were available for 30 of 31 patients, and they ranged from 1.8 to 1062 pg/mL 
with the majority (12/30, 40%) having initial levels of ≤ 10 pg/mL. Twelve of 30 (40.0%) 
patients with measured inhibin levels had pretreatment levels of ≤ 10 pg/mL. Ten of 23 
(33.3%) had a value in the range of 11–100 pg/mL. Eight patients (26.7%) had a 
pretreatment inhibin value of N 100 pg/mL. The pretreatment inhibin level for the single 
patient who experienced a complete response was 88 pg/mL. Over half of the patients 
enrolled received greater than five cycles of treatment. The range of treatment cycles was 1–
46.
3.2. Patient response
There was one complete response (3.2%, 80% CI: [0.74%–15.3%]) and 8 (25.8%) partial 
responses. Fifteen (48.4%) patients had stable disease while six (19.3%) patients progressed 
on treatment. One patient was indeterminate. At the time of analysis, 27 of 31 (87.1%) had 
progressed. Sixteen (51.6%) were dead of disease and 11 (35.5%) were alive with 
progression. Only four (12.9%) were alive without progression of disease. The median 
duration of follow-up among those who were alive at last contact was 5.6 years. Median 
progression-free survival (PFS) was 10.0 months and overall survival was 73.6 months. 
Treatment response is shown in Table 2, and survival curves are shown in Fig. 1.
3.3. Toxicity
Adverse events were classified and graded based on Common Toxicity Criteria version 2.0. 
Myelosuppression was common, with 12 of the 31 patients (38.7%) experiencing at least 
one instance of grade 3 or grade 4 neutropenia (11 individuals), leukopenia (2 individuals), 
or anemia (1 individual). Grade 2 dermatologic adverse events were reported in 19/31 
(61.3%). There were no deaths attributed to the study treatment. Overall, the treatment was 
well-tolerated.
4. Discussion
In our study of 31 patients only one had a complete response. According to the primary 
objective of the study, our data do not justify continuing to evaluate single agent paclitaxel 
administered every three weeks for women with recurrent measurable malignant stromal 
tumor of the ovary. Alternatively, paclitaxel may be evaluated with a different administration 
schedule. We delivered paclitaxel on day one every three weeks at 175 mg/m2. In epithelial 
ovarian cancer, the Japanese GOG demonstrated that weekly (dose-dense) paclitaxel 
improved median PFS and 3 year survival, with a continuation of this trend at a median 
follow-up of 6.4 years [13,14]. Weekly paclitaxel may have an anti-angiogenic effect in 
epithelial ovarian cancer. A similar anti-angiogenic effect due to dose-dense paclitaxel may 
also occur in stromal cell tumors of the ovary. A recent GOG phase 2 trial demonstrated the 
efficacy and safety of bevacizumab in recurrent sex cord stromal ovarian tumors with a 
16.7% partial response rate and 77.8% patients with stable disease [15]. In this GOG phase 2 
trial, patients were allowed unlimited prior therapy with the exception of bevacizumab. 
Thirty-three of 36 patients (91.7%) had received prior chemotherapy with a median of two 
prior regimens. 6 patients had had prior radiation therapy. This trial concluded that 
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bevacizumab had activity in recurrent sex cord stromal tumors. It may be reasonable for 
future trials to include a dose-dense approach to paclitaxel administration in an effort to 
mimic the anti-tumorigenic effects of biologics such as bevacizumab, but with a different 
toxicity profile.
Brown et al. compared BEP to taxane-based therapy. In this retrospective study the authors 
found that while patients treated with BEP had a higher response rate than those treated with 
taxanes, the difference was not statistically significant. However, there was a better toxicity 
profile for the group who received taxane as a single agent. Additionally, they suggested that 
the taxane group may have had a more durable response. However, when the taxane arm 
excluded those patients that received platinum in combination, the response rate was 
considerably lower (18% versus 60%) [16]. This retrospective study evaluated patients who 
received platinum combination therapy with those who received single agent taxane therapy. 
At the same time, our prospective trial was underway to evaluate single agent paclitaxel 
without the addition of a platinum agent.
The prognostic factors associated with survival in stromal tumors of the ovary range widely, 
from tumor size to stage. Prior studies generally included only small numbers of patients, 
and therefore there is much variation when drawing conclusions about prognostic factors.
Inhibin A and inhibin B as well as anti-Mullerian hormone may be effective tumor markers 
for recurrence or progression of disease in sex cord stromal tumors of the ovary [17,18]. 
Pretreatment inhibin levels were available in 30 patients. Twelve of 30 patients had 
pretreatment inhibin levels at ≤ 10 pg/mL. Thus, inhibin may not always be an effective 
tumor marker particularly if it not elevated at the time of recurrence. As there is no 
prospective trial of stromal tumors that report inhibin levels, future trials should investigate 
inhibin A and inhibin B levels prior to treatment and the correlation of levels with response 
to treatment.
Suri et al. found that diabetes had an associated increased risk of recurrent ovarian granulosa 
cell tumor with a hazard ratio of 3.19 [19]. In their study, 20% of the population had 
diabetes, so the data may not have been applicable to a larger, more diverse population. 
Metformin, an anti-diabetic medication from the biguanide class, is at the center of exciting 
and relatively new investigation. Recent epidemiologic evidence suggests that metformin use 
lowers cancer risk and reduces cancer deaths among diabetic patients. [20–22]. Metformin 
has an anti-tumorigenic which effect may be due to the reduction of circulating insulin 
levels, or a direct action in the inhibition of the mTOR pathway. The GOG is currently 
studying patients with advanced or recurrent endometrial cancer. Many stromal tumors of 
the ovary are similarly hormone-driven, therefore, it is possible that metformin has a role in 
the adjuvant treatment of this rare tumor.
A variety of novel biologic agents are currently being evaluated for activity in stromal cell 
tumors. Enzatulamide is a new generation of anti-androgenic agent approved for prostate 
cancer [23]. Enzatulamide's target is steroidogenesis by way of CYP17 inhibition. Total 
ablation of androgen production by potent CYP17 inhibition is the goal of enzatulamide and 
many other agents [24]. Androgen receptors are abundant in granulosa cell tumors. When 
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the FOXL2 gene is mutated, it causes increased CYP17 expression and subsequent increase 
in androgen synthesis. As the mutated FOXL2 gene results in an increased CYP17 
expression, it follows that inhibition of this enzyme may reverse the effect of the FOXL2 
gene mutation. Additional inhibition of CYP17 may be achieved by other novel agents such 
as abiraterone, also used in prostate cancer, as well as ketoconazole, which has been used in 
granulosa cell ovarian tumors [24,25]. Bevacizumab and other antiangiogenesis agents such 
as cediranib are also being studied in recurrent stromal tumors of the ovary [26].
As the armamentarium of active agents against advanced or recurrent stromal ovary tumors 
increases, cytotoxic agents remain among the most active. While single agent paclitaxel did 
not produce a robust response in the patients enrolled in this trial, there may be a role for 
dose-dense paclitaxel or the combination of paclitaxel and novel biologic agents in the 
treatment of advanced or recurrent stromal tumor of the ovary. We reaffirm that the toxicity 
of paclitaxel at the dose and regimen described is acceptable. In the case of malignant 
stromal ovarian tumors, rarity coupled with the indolent nature and overall good prognosis 
in early stage, makes prospective studies difficult. It took 13 years to accrue 31 patients with 
measurable recurrent disease. We must continue to work within the constraints that are 
inherent in studying the rare and indolent tumor that is stromal tumor of the ovary. Current 
clinical trials are decreasing the length of time for accrual by fostering international 
relationships and scientific collaboration [27]. Among other methods, international 
collaboration will allow more rapid study of rare tumors which are inherently difficult to 
study.
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HIGHLIGHTS
• Paclitaxel has activity in recurrent, malignant stromal tumor of the 
ovary.
• There was a complete response in 3.2% and partial response in 25.8% 
of women.
• • Inhibin is not a reliable tumor marker.
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Fig. 1. 
Median duration of follow-up for patients who were alive at last contact is 5.6 years.
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Table 1
Patient characteristics.
Characteristics No. of cases % of cases
Age
<40 7 22.6
40–49 8 25.8
50–59 9 29.0
≥60 7 22.6
Race
Non-Hispanic Black 7 22.6
Non-Hispanic White 18 58.1
Hispanic 2 6.4
Asian/Pacific Islander 4 12.9
Disease status
Previously untreated 0 0.0
Recurrent disease 31 100.0
Performance status
0 25 80.6
1 5 16.1
2 1 3.2
Prior radiotherapy
Yes 3 9.7
No 28 90.3
Prior immunotherapy
Yes 1 3.2
No 30 96.8
Prior chemotherapy
Yes 24 77.4
No 7 22.6
Prior hormone therapy
Yes 3 9.7
No 28 90.3
Pretreatment Inhibin (pg/mL)
≤10 12 38.7
11–100 10 32.2
>100 1 3.2
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Table 2
Clinical response.
Characteristics No. of cases % of cases
Response
Complete response 1 3.2
Partial response 8 25.8
Stable disease 15 48.4
Increasing disease 6 19.3
Indeterminate 1 3.2
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